Takeda’s CMV Infection ‘Game-Changer’ Among EU Fast-Track Hopefuls

Calliditas Also Wants Accelerated Assessment For Novel Budesonide Drug

Takeda, Calliditas and Bayer are set to learn whether the European Medicines Agency will grant their respective products accelerated assessment status when they file for pan-EU marketing approval.

Companies have asked the EMA to speed up its review of their products • Source: Alamy

The European Medicines Agency is this week deciding whether to fast track the planned EU marketing applications for three products, including maribavir, Takeda Pharmaceutical’s oral antiviral agent that the company claims could be a game-changer treatment for post-transplant cytomegalovirus (CMV) infection.

Maribavir is on track to being filed for approval in the EU and the US in the first half of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography